Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR-T for Postoperative MRD in Colorectal Cancer with Liver Metastases
NCT05240950Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CEA-CART in colorectal cancer (CRC) and liver metastases, sponsored by Changhai Hospital. Primary endpoints: Incidence and severity of adverse events at 28 days, Effectiveness (minimal residual disease) at 24 months and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
CEA-CART
03
Conditions
colorectal cancer (CRC)liver metastases
Beyond the preview
Go deeper on NCT05240950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240950.